AKT1 and cancer: The main pathways of enrichment included EGFR tyrosine kinase inhibitor resistance, the MAPK signaling pathway, Ras signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, osteoclast differentiation, IL-17 signaling pathway, proteoglycans in cancer, prostate cancer, and melanoma.